Goodman, Wendy A. http://orcid.org/0000-0002-6864-0384
Basavarajappa, Shrikanth C.
Liu, Angela R.
Rodriguez, Franklin D. Staback
Mathes, Tailor
Ramakrishnan, Parameswaran http://orcid.org/0000-0002-1314-827X
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01 AI116730, R21 AI144264)
National Cancer Institute (R21 CA246194)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097948, K01 DK105138, R03 DK123579)
Crohn's and Colitis Foundation of America (635911)
Article History
Received: 22 April 2021
Revised: 29 September 2021
Accepted: 9 October 2021
First Online: 24 October 2021
Declarations
:
: PR has a patent on the use of Sam68 for modulating signaling through the TNF receptor (US8598137B2). Other authors have declared that no conflict of interest exists.
: All mouse studies were approved under CWRU IACUC protocol 2013-0134. All human tissue samples used in this study were slated to be discarded samples that were deidentified and procured through the Cleveland Digestive Disease Research Biorepositoy Core facility with non-human subject research IRB approval from University Hospitals, IRB number NHR-16-103 and STUDY20210825.
: Not applicable. No human subjects were recruited for this study.
: Not applicable.